Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI

Conditions: To Investigate the Potential Value of CDK4/6 Inhibitor in NSCLC Patients Undergoing Acquired Resistance to Third-generation EGFR TKIs Interventions: Drug: Osimertinib plus Dalpiciclib Sponsors: Tianjin Medical University Cancer Institute and Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials